EichorEICHOR
Condition: Aml Stage Adult Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Aml Stage Adult

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Phase 3 · 48 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04168502Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel
Phase 2 · 7 location(s) · National Cancer Institute (NCI) · NCT07437950VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT05603884Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT06802315Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19
Phase 1 · 1 location(s) · University Hospital, Lille · NCT06649227TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06206174Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Phase 1 · 3 location(s) · Meryx, Inc. · NCT04872478Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210Venetoclax to Augment Epigenetic Modification and Chemotherapy
Phase 1 · 1 location(s) · Medical College of Wisconsin · NCT05317403L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adu
Phase 2/Phase 3 · 28 location(s) · Moleculin Biotech, Inc. · NCT06788756Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Nerviano Medical Sciences · NCT06549790AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
Phase 2/Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT05404906A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Com
Phase 2/Phase 3 · 11 location(s) · AbbVie · NCT07581002Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients o
Phase 1 · 1 location(s) · Nantes University Hospital · NCT05749276CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Phase 2 · 1 location(s) · University of Maryland, Baltimore · NCT04050280Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin
Phase 2 · 36 location(s) · National Cancer Institute (NCI) · NCT06917911Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
Phase 3 · 51 location(s) · PETHEMA Foundation · NCT07478991Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Hangzhou Weben Pharma Co., Ltd · NCT070144493'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Trea
Phase 2 · 227 location(s) · National Cancer Institute (NCI) · NCT06317649Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Phase 1 · 2 location(s) · Remedy Plan, Inc. · NCT07107126A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H
Phase 1 · 18 location(s) · AstraZeneca · NCT05877599A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Phase 1 · 3 location(s) · Cullgen (Shanghai),Inc · NCT07347171HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Phase 3 · 111 location(s) · Priothera SAS · NCT05429632Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Pa
Phase 1/Phase 2 · 34 location(s) · Aptose Biosciences Inc. · NCT03850574Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854Revumenib in Combination With 7+3 + Midostaurin in AML
Phase 1 · 2 location(s) · Richard Stone, MD · NCT06313437A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
Phase 1 · 1 location(s) · Zhejiang ACEA Pharmaceutical Co. Ltd. · NCT05947344CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05672147
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.